WestlakeWJ. Bioavailability and bioequivalence of pharmaceutical formulations. In: PeaceKE, ed. Biopharmaceutical statistics for drug development. New York: Marcel Dekker; 1988: 329–352.
2.
PeaceKE, ed. Biopharmaceutical statistics for drug development. New York: Marcel Dekker; 1988.
3.
SchuirmannDJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmaco Biopharm.1987;15(6):657–680.
4.
WestlakeWJ, in response to Kirkwood TBL. Bioequivalence testing: A need to rethink. Biometrics.1981;37: 589–594.
5.
KershnerRPFedererWT. Two-treatment crossover designs for estimating a variety of effects. J Amer Stat Assoc.1981;76: 612–619.
6.
FleissJL. On multiperiod crossover studies. Biometrics.1986;42(2):449–450.
7.
ChinchilliVM. Clinical efficacy trials with quantitative data. In: PeaceKE, ed. Biopharmaceutical statistics for drug development. New York: Marcel Dekker; 1988: 353–402.
8.
HwangSHuberPBHesneyMKwanKC. Bioequivalence and interchangeability. J Pharm Sci.1978;67(6):IV (“Open Forum”).
